Core Viewpoint - The company has proposed a mid-term profit distribution plan for 2025, which includes a cash dividend of 2.00 yuan per 10 shares, based on a total share capital of 1,972,852,683 shares after deducting repurchased shares [7][34]. Company Overview - The company is named Huabang Life Health Co., Ltd. and is listed under the stock code 002004 [1]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period [6]. Financial Data and Indicators - For the first half of 2025, the company reported a net profit attributable to shareholders of 388,455,625.50 yuan, with available profits for distribution amounting to 775,936,281.82 yuan [7][8]. - The total profit available for distribution as per the consolidated financial statements is 1,986,457,656.65 yuan [7]. Profit Distribution Plan - The profit distribution plan includes a cash dividend of 394,570,536.60 yuan (including tax), with no stock dividends or capital reserve transfers [8][9]. - The plan is designed to enhance the company's investment value and share the growth results with investors, ensuring that it does not affect the company's liquidity or debt repayment capacity [9]. Shareholder Meeting - The company will hold its first extraordinary general meeting of 2025 on September 5, 2025, to review the proposed profit distribution plan [12][15]. - The meeting will be conducted both in-person and via online voting, with a registration deadline of September 2, 2025 [15][16]. Performance Presentation - The company will hold a performance presentation on August 26, 2025, to further inform investors about its operational status for the first half of 2025 [30][31]. - Investors are encouraged to submit questions in advance to enhance the relevance of the discussion during the presentation [31].

Core Insights - Company reported a revenue of 5.945 billion yuan for the first half of 2025, a year-on-year increase of 0.39%, and a net profit attributable to shareholders of 388 million yuan, a significant increase of 23.9% [1] - The company plans to distribute a cash dividend of 2 yuan per 10 shares, reflecting its commitment to shareholder returns [1] - The company has established a diversified structure with a focus on the health industry, covering five major sectors: pharmaceuticals, medical services, agrochemicals, new materials, and tourism [1] Pharmaceutical Sector - The company has strengthened its R&D investment, with several products receiving approvals, including the first generic version of calcipotriol betamethasone ointment, marking a significant breakthrough in psoriasis treatment [2] - The company is consolidating its prescription market advantage while actively expanding into domestic and overseas raw material markets, and has launched functional skincare products to enhance its product matrix [2] Medical Sector - The company has added new specialty clinics in its Chongqing Songshan Hospital, enhancing its medical service capabilities and achieving steady growth in consumer healthcare and health management [2] - The Beijing Huasheng Rehabilitation Hospital has increased its bed capacity to 457, with a steady rise in patient visits and solid progress in key rehabilitation disciplines [2] Agrochemical Sector - The agrochemical sector is experiencing a recovery in profitability due to improved supply-demand dynamics and price increases in certain product segments [3] - The company’s agrochemical business is stabilizing and contributing to overall performance growth [3] New Materials Sector - The new materials sector has seen an increase in orders and improved gross margins due to recovering demand and cost advantages [3] Tourism Sector - The tourism sector continues to show steady improvement, with the company actively seizing industry opportunities and enhancing market competitiveness [3] Strategic Focus - The company aims to continue developing a full industry chain model centered on "big health," integrating raw materials, formulations, functional skincare, health management, and medical services for sustainable long-term growth [3]

Group 1: Company Performance - Xiaomi Group reported total revenue of 116 billion yuan for Q2 2025, a year-on-year increase of 30.5%, with adjusted net profit of 10.8 billion yuan, up 75.4% [1] - Pop Mart achieved revenue of 13.88 billion yuan in the first half of the year, a significant year-on-year growth of 204.4%, with adjusted net profit of 4.71 billion yuan, up 362.8% [2] - Xian Da Co. reported a net profit of 136 million yuan for the first half of 2025, a staggering year-on-year increase of 2561.58%, with revenue of 1.423 billion yuan, up 11.82% [3] - Huabang Health's net profit increased by 23.90% in the first half of the year [14] - Fuyao Glass's net profit grew by 37% in the first half of the year [14] - Jibite's net profit rose by 24.50% in the first half of the year, with a proposed dividend of 66 yuan for every 10 shares [14] - Meihua Biotech's net profit increased by 19.96% in the first half of the year [14] - Tiancheng Technology's net profit saw a slight increase of 0.22% in the first half of the year [14] - Zoli Pharmaceutical's net profit grew by 26.16% in the first half of the year [14] - Yuyin Co.'s net profit increased by 10.43% in the first half of the year [14] - Nuo Ping's net profit rose by 17.35% in the first half of the year [14] - Jinli Permanent Magnet's net profit surged by 155% in the first half of the year, proposing a dividend of 1.8 yuan for every 10 shares [14] - Huacheng Film's net profit increased by 65.05% in the first half of the year [14] - YTO Express reported a 12.08% year-on-year increase in express product revenue in July [14] - Zhongxin Special Steel's net profit for the first half of the year was 2.798 billion yuan, up 2.67% [14] Group 2: Corporate Actions - Dongjie Intelligent announced plans for a change in control, leading to a temporary suspension of its stock and convertible bonds [4] - Dameng Data's general manager is under investigation, but the company expects no significant impact on operations [5] - Jiangte Electric announced that its subsidiary Yichun Silver Lithium will resume production soon after equipment maintenance [6] - Garden Shares clarified that it does not have a controlling relationship with Yunzhin Technology, which is still in the early stages of technology commercialization [7] - Daikin Heavy Industries completed the delivery of all monopile products for the Nordseecluster offshore wind farm project, which is the largest offshore wind farm under construction in Germany [8] - Zhongyin Securities plans to increase capital by 1.4 billion yuan to its wholly-owned subsidiary Zhongyin International Investment [13] - Xinhongye intends to acquire 62% of Yangzhou Shuguang Optoelectronic Control Co., Ltd. [16] - A joint venture led by Tongyuan Environment won a bid for the expansion project of the sewage treatment plant in Anhui Qimen Economic Development Zone [17]

（文章来源：证券日报） 证券日报网讯 8月19日晚间，华邦健康发布公告称，公司将于2025年9月5日召开2025年第一次临时股东 会。本次股东会将审议《2025年中期利润分配预案》。 ...

证券日报网讯 8月19日晚间，华邦健康发布公告称，公司第九届董事会第二次会议审议通过了《关于召 开2025年第一次临时股东会的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 8月19日晚间，华邦健康发布2025年半年度报告摘要称，2025年半年度公司实现营业收入 为5，945，032，088.09元，同比增长0.39%；实现归属于上市公司股东的净利润为388，455，625.50 元，同比增长23.90%。 （编辑 任世碧） ...

公司上市以来历次分配方案一览 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 资金面上看，该股今日主力资金净流出243.59万元，近5日主力资金净流入4078.61万元。 两融数据显示，该股最新融资余额为3.74亿元，近5日增加2327.96万元，增幅为6.65%。 按申万行业统计，华邦健康所属的医药生物行业共有15家公司公布了2025半年度分配方案，派现金额最 多的是药明康德，派现金额为10.03亿元，其次是华润三九、白云山，派现金额分别为7.51亿元、6.50亿 元。（数据宝） 2025半年度医药生物行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额（万 | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | | | | （股） | （元） | 元） | （%） | （%） | | 603259 | 药明康 德 | 0.00 | 3.5 | 100308.38 | 11.72 | 0.58 | | 000999 | 华润三 九 | 0.00 | 4.5 | 7513 ...

资料显示，华邦健康成立于1992年，是国内皮肤临床用药及皮肤健康领域企业，经过三十多年的耕耘， 形成了以大健康产业为核心，农化、新材料、旅游三家上市公司独立发展的模式。目前公司业务范围涵 盖医药、医疗、农化、新材料、旅游等五大领域，旗下共控股三家上市公司，分别为颖泰生物 (920819.BJ)、凯盛新材(301069.SZ)、丽江股份(002033.SZ)。 北京商报讯（记者 丁宁）8月19日晚间，华邦健康（002004）披露半年报显示，公司上半年实现营业收 入59.45亿元，同比增长0.39%；归属净利润3.88亿元，同比增长23.9%。 ...

人民财讯8月19日电，华邦健康（002004）8月19日晚间披露2025年半年报，公司上半年实现营业收入 59.45亿元，同比增长0.39%；归母净利润3.88亿元，同比增长23.9%；基本每股收益0.1969元。公司拟每 10股派发现金红利2元(含税)。报告期内，农化板块需求回暖，带动公司农化相关产品的订单增加。同 时，原材料液氯采购价格维持相对低位，多因素协同发力，公司主要产品的出货量及毛利均有所上升, 推动公司业绩较去年同期增长明显。 ...

Core Viewpoint - The financial report of Huabang Life Health Co., Ltd. for the first half of 2025 shows a slight increase in total revenue and a significant rise in net profit compared to the same period in 2024, indicating a positive financial performance despite some fluctuations in costs and expenses [1]. Financial Statements Assets - Total assets at the end of the period amounted to 29,654,478,331.32 yuan, an increase from 29,450,469,334.61 yuan at the beginning of the period [2][3]. - Current assets totaled 11,538,794,816.33 yuan, up from 11,276,705,434.24 yuan [2]. - Non-current assets were reported at 18,115,683,514.99 yuan, slightly down from 18,173,763,900.37 yuan [2]. Liabilities - Total liabilities decreased to 13,690,632,642.71 yuan from 13,977,060,015.24 yuan [3]. - Current liabilities were 9,379,962,735.70 yuan, down from 10,415,060,826.26 yuan [3]. - Non-current liabilities increased to 4,310,669,907.01 yuan from 3,561,999,188.98 yuan [3]. Equity - Total equity rose to 15,963,845,688.61 yuan from 15,473,409,319.37 yuan [3]. - The company's retained earnings increased to 1,986,457,656.65 yuan from 1,598,002,031.15 yuan [3]. Income Statement - Total operating revenue for the first half of 2025 was 5,945,032,088.09 yuan, slightly up from 5,922,042,354.85 yuan in the same period of 2024 [4]. - Total operating costs decreased to 5,353,287,909.61 yuan from 5,370,629,390.07 yuan [4]. - Net profit for the period was 549,873,387.16 yuan, compared to 424,208,862.87 yuan in the previous year, reflecting a significant increase [5]. Cash Flow Statement - Net cash flow from operating activities was 536,502,508.00 yuan, an increase from 367,219,592.32 yuan [6]. - Net cash flow from investing activities was 263,981,575.71 yuan, a turnaround from a negative cash flow of -534,976,367.90 yuan [6]. - Net cash flow from financing activities was -517,407,309.94 yuan, compared to a positive cash flow of 306,299,407.34 yuan in the previous year [6].